Amazon Prime Day isn't over just yet: The online retail giant is still dishing out deals on thousands of its best-selling products. Just when you thought you were all shopped out, Amazon rolls out ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the companies said Monday. Regeneron said it will comply with 23andMe’s privacy ...

The settlement highlights the lasting risks of exposing genetic data that can’t be changed or replaced.

Regeneron Pharmaceuticals will acquire 23andMe's assets for $256 million, both companies said. 23andMe filed for Chapter 11 bankruptcy earlier this year. The DNA testing company has faced major ...

Following a data breach and bankruptcy, genetic testing service 23andMe will soon be in different hands. On Monday, biotechnology company Regeneron announced that it won the top bid in a bankruptcy ...

New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. This year, skip the clutter and gift pure ...

Remember when everyone was discovering they were 12% Scandinavian and posting colorful pie charts of their genetic heritage on social media? Those glory days of DNA testing have come to a stunning end ...

Add Yahoo as a preferred source to see more of our stories on Google. Regarding 23andMe’s massive DNA database, Regeneron said it plans to process the data “in ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million. The ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ offer for the DNA-testing company in a bankruptcy auction.